IDEAYA Biosciences, Inc. announced the development candidate nomination of IDE892 on December 9, 2024. IDE892 is a potential best-in-class MTA-cooperative PRMT5 inhibitor, representing the company's seventh development candidate.
IDE892 was discovered through IDEAYA's physics-based ligand design and optimization platform, demonstrating high potency, selectivity, and favorable drug-like properties. Preclinical studies showed exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models.
The program aims to enable a wholly-owned combination between the PRMT5 and MAT2A mechanisms, with IDE892 showing durable complete responses in combination with MAT2A inhibitor IDE397 in preclinical models. IND-enabling studies are ongoing, targeting an Investigational New Drug (IND) filing to the U.S. FDA in mid-2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.